LOGIN  |  REGISTER
Amneal Pharmaceuticals
Terns Pharmaceuticals

Penumbra to Present at the J.P. Morgan 42nd Annual Healthcare Conference

December 18, 2023 | Last Trade: US$257.81 5.58 2.21

ALAMEDA, Calif., Dec. 18, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on Monday, January 8, 2024.

Event:     J.P. Morgan 42nd Annual Healthcare Conference
Date:       Monday, January 8, 2024
Time:      11:15am ET/8:15am PT

A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com.  The webcast will be available on the company's website for at least two weeks following the event.

About Penumbra 

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.

Investor Relations
Penumbra, Inc.
510-995-2461
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page